Quick Answer
Silo Pharma, Inc. reported Operating Income Loss of -$4.28 million for the year ending 2025.
- Silo Pharma, Inc. showed an increase of +9.0% in Operating Income Loss from 2024 to 2025.
- This data is from Silo Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$134.9 thousand | Q2 2018: -$76.1 thousand | Q3 2018: -$81.2 thousand | Q1 2019: -$174.6 thousand | Q2 2019: -$189.9 thousand | Q3 2019: -$242.5 thousand | Q1 2020: -$159.4 thousand | Q2 2020: -$996.7 thousand | Q3 2020: -$558.9 thousand | Q1 2021: -$901.1 thousand | Q2 2021: -$436.8 thousand | Q3 2021: -$463.9 thousand | Q1 2022: -$527.3 thousand | Q2 2022: -$494.3 thousand | Q3 2022: -$949.2 thousand | Q1 2023: -$803.5 thousand | Q2 2023: -$1.11 million | Q3 2023: -$773.4 thousand | Q1 2024: -$879.5 thousand | Q2 2024: -$1.00 million | Q3 2024: -$1.01 million | Q1 2025: -$1.09 million | Q2 2025: -$1.25 million | Q3 2025: -$1.15 million.
- Over the full 9 years of available data (2017 to 2025), Silo Pharma, Inc.'s Operating Income Loss has declined by 772.1%.
- Historical annual values: Fiscal year 2025: -$4.28 million | Fiscal year 2024: -$4.71 million | Fiscal year 2023: -$3.86 million | Fiscal year 2022: -$3.63 million | Fiscal year 2021: -$2.74 million | Fiscal year 2020: -$2.20 million | Fiscal year 2019: -$930.4 thousand | Fiscal year 2018: -$594.2 thousand | Fiscal year 2017: -$490.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: